Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.
A Novel Health-Related Quality of Life Assessment Tool for Nontransfusion-Dependent Beta Thalassemia
Modern tools for measuring health-related quality of life may not capture symptoms unique to patients with nontransfusion-dependent thalassemia.
Treatment Success With HLA-Matched Donor Grafts for Beta Thalassemia From Relatives and Nonrelatives
Researchers analyzed 1110 patients who had received transplanted grafts from HLA-matched and mismatched relatives and unrelated donors.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Reduced Need for Red Blood Cell Transfusions in Patients Treated With Luspatercept for Beta-Thalassemia
The drug's ability to boost late-stage erythropoiesis makes it a potential treatment option for patients with beta-thalassemia.
The researchers found that in transplanted patients, the 30-year overall survival (OS) was 82.6±2.7% and thalassemia-free survival (TFS) was 77.8±2.9% compared with OS of 85.3±2.7% in CT patients (P=NS).